ELAN
Price
$19.57
Change
+$0.65 (+3.44%)
Updated
Sep 26, 03:45 PM (EDT)
Capitalization
9.4B
46 days until earnings call
HROW
Price
$47.53
Change
+$1.38 (+2.99%)
Updated
Sep 26, 04:06 PM (EDT)
Capitalization
1.71B
52 days until earnings call
Interact to see
Advertisement

ELAN vs HROW

Header iconELAN vs HROW Comparison
Open Charts ELAN vs HROWBanner chart's image
Elanco Animal Health
Price$19.57
Change+$0.65 (+3.44%)
Volume$7.69K
Capitalization9.4B
Harrow
Price$47.53
Change+$1.38 (+2.99%)
Volume$600
Capitalization1.71B
ELAN vs HROW Comparison Chart in %
Loading...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAN vs. HROW commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Buy and HROW is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (ELAN: $18.92 vs. HROW: $46.15)
Brand notoriety: ELAN: Notable vs. HROW: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 50% vs. HROW: 125%
Market capitalization -- ELAN: $9.4B vs. HROW: $1.71B
ELAN [@Pharmaceuticals: Generic] is valued at $9.4B. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.71B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 3 TA indicator(s) are bullish while HROW’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 3 bullish, 5 bearish.
  • HROW’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, HROW is a better buy in the short-term than ELAN.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а -0.94% price change this week, while HROW (@Pharmaceuticals: Generic) price change was +1.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.63%. For the same industry, the average monthly price growth was +25.30%, and the average quarterly price growth was +68.14%.

Reported Earning Dates

ELAN is expected to report earnings on Nov 11, 2025.

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.63% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($9.4B) has a higher market cap than HROW($1.71B). ELAN YTD gains are higher at: 56.235 vs. HROW (37.556). ELAN has higher annual earnings (EBITDA): 1.45B vs. HROW (32.1M). ELAN has more cash in the bank: 539M vs. HROW (53M). HROW has less debt than ELAN: HROW (231M) vs ELAN (4.21B). ELAN has higher revenues than HROW: ELAN (4.48B) vs HROW (228M).
ELANHROWELAN / HROW
Capitalization9.4B1.71B550%
EBITDA1.45B32.1M4,514%
Gain YTD56.23537.556150%
P/E Ratio21.50N/A-
Revenue4.48B228M1,967%
Total Cash539M53M1,017%
Total Debt4.21B231M1,822%
FUNDAMENTALS RATINGS
ELAN vs HROW: Fundamental Ratings
ELAN
HROW
OUTLOOK RATING
1..100
5719
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
7996
PRICE GROWTH RATING
1..100
4038
P/E GROWTH RATING
1..100
8810
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (85) in the Pharmaceuticals Other industry is in the same range as ELAN (93) in the Agricultural Commodities Or Milling industry. This means that HROW’s stock grew similarly to ELAN’s over the last 12 months.

HROW's Profit vs Risk Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that HROW’s stock grew somewhat faster than ELAN’s over the last 12 months.

ELAN's SMR Rating (79) in the Agricultural Commodities Or Milling industry is in the same range as HROW (96) in the Pharmaceuticals Other industry. This means that ELAN’s stock grew similarly to HROW’s over the last 12 months.

HROW's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as ELAN (40) in the Agricultural Commodities Or Milling industry. This means that HROW’s stock grew similarly to ELAN’s over the last 12 months.

HROW's P/E Growth Rating (10) in the Pharmaceuticals Other industry is significantly better than the same rating for ELAN (88) in the Agricultural Commodities Or Milling industry. This means that HROW’s stock grew significantly faster than ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANHROW
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IVEG21.59N/A
N/A
iShares Emergent Food and AgTech Multisector ETF
DSEP43.89-0.10
-0.23%
FT Vest US Equity Dp Bffr ETF Sep
DFAR23.48-0.06
-0.25%
Dimensional US Real Estate ETF
IBMS26.10-0.07
-0.25%
iShares iBonds Dec 2030 Term Mun Bd ETF
FPFD22.18-0.06
-0.28%
Fidelity Preferred Securities & Inc ETF

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+0.91%
VTRS - ELAN
54%
Loosely correlated
-2.27%
ZTS - ELAN
47%
Loosely correlated
-0.38%
EBS - ELAN
39%
Loosely correlated
+5.43%
PAHC - ELAN
39%
Loosely correlated
-0.55%
AMRX - ELAN
36%
Loosely correlated
-1.13%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-3.61%
OGI - HROW
34%
Loosely correlated
-3.31%
TKNO - HROW
33%
Loosely correlated
+2.12%
AMRX - HROW
32%
Poorly correlated
-1.13%
ELAN - HROW
30%
Poorly correlated
+0.91%
ANIP - HROW
29%
Poorly correlated
-1.71%
More